Chloroquine and hydroxychloroquine as available weapons to fight COVID-19

By Philippe Colson, J.-M. Rolain, J. Lagier, P. Brouqui, Didier Raoult. International Journal of Antimicrobial Agents, 2020

822 citations recorded by the source corpus.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Subfields: Infectious Diseases, Nutrition and Dietetics, Pharmacology

View Paper: https://www.semanticscholar.org/paper/c2881b37e62009016feb5cf5d985ef377fa3f622

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. J. Lagier
2. B. La Scola
3. P. Gautret
4. P. Parola
5. M. Million
6. Didier Raoult
7. P. Fournier
8. V. Hoang

Citations in the corpus

• Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State (2020, neutral): “5) [20] 28 (26-30) [17] 31 (NA) [1]d 25 (21-26) [7]”
• Novel 2019 coronavirus structure, mechanism of action, antiviral drug promises and rule out against its treatment (2020, neutral): “Colson group have suggested that chloroquine and hydroxychloroquine as available weapons to fight COVID-19 (Colson et al., 2020).”
• New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? (2020, positive): “he worldwide ongoing trials, including those involving the care of atients in our institute [90] , will verify whether the hopes raised y chloroquine in the treatment of COVID-19 can be confirmed.”
• Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. (2020, neutral): “7) ICU: 52 (100); ARDS: 35 (67); MI: 12 (23); AKI: 15 (29); bacterial infection: 8 (15) ICU: 2 (11); ARDS: 0 (0); secondary bacterial infection: (0) ICU: 1 (8); culture-positive secondary bacterial infection: 0 (0) ICU: 55 (5); ARDS: 37 (3.”
• Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study (2020, positive): “Among the candidate drugs to treat COVID-19, repositioning old drugs for use as an antiviral treatment is a compelling strategy, because knowledge about these drugs’ safety profile, side effects, pharmacokinetics and drug interactions are already well known [6,7].”
• Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial (2020, positive): “Among candidate drugs to treat COVID-19, repositioning of old drugs for use as antiviral treatment is an interesting strategy because knowledge on safety profile, side effects, posology and drug interactions are well known [6,7].”
• The epidemiology, diagnosis and treatment of COVID-19 (2020, neutral): “The optimal dosage of chloroquine for SARS-CoV-2 will need to be assessed in future trials [62] .”